The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia (INERTIA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04255745|
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 6, 2020
|Condition or disease||Intervention/treatment||Phase|
|Sarcopenia High Blood Pressure Hypertension||Behavioral: progressive resistance training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||permuted block randomization scheme,|
|Masking Description:||Primary investigator will be masked to the outcome data collection|
|Official Title:||The Impact of a Resistance Training Intervention on Blood Pressure Control in Older Adults With Sarcopenia|
|Actual Study Start Date :||January 27, 2020|
|Estimated Primary Completion Date :||March 2023|
|Estimated Study Completion Date :||March 2024|
No Intervention: Assessment-only control
30 Assessment-only control group will be mailed (standard or electronic) NIH/National Institutes on Aging (NIA) Go4Life® educational materials once a month for 3 months. Exercise logs documenting weekly exercise activities, duration, time and effort will be requested to be sent back.
60 Intervention group will receive 12 weeks of supervised resistance training following the American Heart Association and American College of Sports Medicine guidelines for older adults. Exercises will include a mixture of upper-body and lower body strength exercises. Training load will be determined based on initial 1-repetition maximum tests (1-RM). Initial exercise load will start off at low resistance (40-50% 1RM) with more frequent repetitions per exercise, and will gradually increase weight load and intensity over the exercise training period.
Behavioral: progressive resistance training
Individual, tailored, progressive muscle strength and function intervention
- Change in systolic and diastolic blood pressure [ Time Frame: baseline, 12 weeks, 1 year ]
- Short Physical Performance Battery (SPPB) [ Time Frame: baseline, 12 weeks, 1 year ]4 meter gait speed (m/s; slow speed indicates lower function), timed five-time-sit-to-stand (in seconds, slower time indicates lower function), 3-stage balance (3 positions total, scored separately; inability to hold each position for 10seconds each indicates lower function)
- Timed up and go performance [ Time Frame: baseline, 12 weeks, 1 year ]change in timed up and go (slower time indicates lower function)
- Muscle strength [ Time Frame: baseline, 8 weeks 12 weeks, 1 year ]
muscle strength will be assessed using the 1 Repetition maximum test ( the maximum amount of weight a person can hold while performing an exercise safely and maintaining form. the 1RM will be tested on upper and lower body for a total of 6 exercises, as recommended by the American College of Sports Medicine. Changes in 1RM will be reevaluated to see if strength improves.
- chest press
- leg press
- lat-pull down
- leg extensions
- shoulder press
- leg curls
- Microvascular flow-induced vasodilation (FID) dose response [ Time Frame: baseline, 12 weeks ]Microvessels in subcutaneous fat (SF) will be extracted from 10 intervention and 5 control subjects (total=15) and isolated for microvascular flow-induced vasodilation (FID). Microvessels will be constricted to physiological and pharmacological pressures (stimuli) followed by dialation by a vasodialtor. The dose response curves to vasodialator will be measured (known as FID dose-response) will be the primary outcome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04255745
|Contact: Deepika Laddu, PhDfirstname.lastname@example.org|
|Contact: Nidhi Choudharyemail@example.com|